Drug intelligence / Profile preview

smart glucagon

Development stage: Preclinical
Lead developer: Eli Lilly
Modality: Peptides, Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

"Smart glucagon" is a glucose-responsive glucagon developed by Protomer Technologies, which was acquired by Eli Lilly in July 2021. This therapeutic candidate is designed to prevent hypoglycemia by automatically activating and releasing glucagon when blood glucose levels fall dangerously low. It aims to work in conjunction with normal insulin treatment, potentially eliminating the need for a separate rescue glucagon kit. The development of smart glucagon leverages Protomer's proprietary Molecular Engineering of Protein Sensors (MEPS) platform.

Other names: glucose-responsive glucagon

Targets

GCGR (Glucagon receptor)

Beyond the preview

Go deeper on smart glucagon.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on smart glucagon.

Explore the full profile